Peter Frampton will be saluted on May 15th at Cleveland's Rock and Roll Hall of Fame as one of the 2020 Rare Impact Award honorees from the National Organization for Rare Disorders (NORD). Frampton, who wrapped an exhaustive North American trek back in October, has been forced to quit the road upon discovering he's suffering from a degenerative muscle disease called Inclusion-Body Myositus (IBM), that slowly weakens the body's muscles. He'll play his final shows this spring in Europe.
According to the NORD press release, “These exceptional individuals, organizations, and industry innovators will be honored for their outstanding work for the rare disease community by NORD, the leading independent advocacy organization dedicated to improving the lives of patients and families impacted by rare diseases.”
During his chat with CBS, Peter Frampton spoke about how IBM affects the body: “For a guitar player, it's not so good. But, I'm able to play great — right now. In a year's time, maybe not so good. I'm a perfectionist and I do not wanna go out there and feel like, 'Oh, I can't. . . this isn't good'; that would be a nightmare for me. 'Cause it's my passion. I've been playing guitar for 60 years — started when I was eight. So, I've had a very good run. I know that I will be at the top of my game for this tour, and I will make it through this, and people won't be say 'Ohhh — he can't play as good. . .' I can, y'know? But, we just don't know for how long.”
